Age (years)
|
38 (20-51)
|
17 (2-51)
|
0.013
|
Gender (male)
|
89 (56.0)
|
19 (47.5)
|
0.456
|
Underlying disease
| | |
0.320
|
Acute myeloid leukemia
|
117 (73.6)
|
28 (70.0)
| |
Acute lymphoblastic leukemia
|
26 (16.4)
|
9 (22.5)
| |
Other leukemias
|
6 (3.1)
|
1 (2.5)
| |
Non-Hodgkin lymphoma
|
8 (5.0)
|
1 (2.5)
| |
Multiple myeloma
|
2 (1.3)
|
1 (2.5)
| |
Complete remission status
|
104 (65.4)
|
19 (47.5)
|
0.037
|
Preceding therapy
| | |
0.732
|
Conventional chemotherapy
|
151 (95.0)
|
38 (95.0)
| |
Hematopoietic cell transplantation
| | | |
Autologous
|
6 (3.8)
|
2 (5.0)
| |
Allogeneic
|
2 (1.3)
|
0 (0.0)
| |
Duration after the preceding therapy (days)
|
12 (10-14)
|
13 (10-13)
|
0.568
|
Antibacterial prophylaxis*
| | |
<0.001
|
None
|
4 (2.5)
|
1 (2.7)
| |
Trimethoprim/sulfamethoxazole
|
31 (19.5)
|
20 (54.1)
| |
Ciprofloxacin
|
124 (78.0)
|
16 (43.2)
| |
Probability of antibacterial therapy after chemotherapy† (%)
|
84.0 ± 29.6
|
81.8 ± 32.0
|
0.864
|
Previous antibacterial therapy for febrile neutropenia† (times)
|
1 (1-2)
|
2 (1-2)
|
0.284
|
Accompanying symptoms
| | | |
Oral mucositis
|
35 (22.0)
|
6 (15.0)
|
0.327
|
Cough
|
18 (11.3)
|
2 (5.0)
|
0.377
|
Sputum
|
6 (3.8)
|
3 (7.5)
|
0.388
|
Rhinorrhea
|
1 (0.6)
|
0 (0.0)
|
1.000
|
Diarrhea
|
50 (31.4)
|
8 (20.0)
|
0.154
|
Abdominal pain
|
34 (21.4)
|
4 (10.0)
|
0.102
|
Polymicrobial infection
| | | |
Other bacterial infection
|
17 (10.7)
|
5 (12.5)
|
0.779
|
Fungal infection
|
16 (10.1)
|
2 (5.0)
|
0.537
|
Complications attributable to VSB
|
23 (14.5)
|
3 (7.5)
|
0.243
|
Ventilator care
|
8 (5.0)
|
0 (0.0)
|
0.362
|
Acute respiratory distress syndrome
|
6 (3.8)
|
0 (0.0)
|
0.602
|
Shock
|
23 (14.5)
|
3 (7.5)
|
0.243
|
Death
|
4 (2.5)
|
0 (0.0)
|
0.585
|
Overall death
|
13 (8.2)
|
1 (2.5)
|
0.309
|
Laboratory findings
| | | |
White blood cell count (/μL)
|
60 (20-160)
|
40 (20-118)
|
0.194
|
Absolute neutrophil count (/μL)
|
0 (0-0)
|
0 (0-0)
|
0.915
|
Duration of neutropenia before the diagnosis of VSB (days)
|
5 (4-7)
|
7 (5-11)
|
0.021
|
Total duration of neutropenia (days)
|
16 (12-23)
|
20 (12-24)
|
0.094
|
Peak C-reactive protein level (mg/dL)
|
19.6 (13.1-26.1)
|
17.1 (9.3-28.1)
|
0.397
|